Abstracts tagged "Uric Acid, Urate"

Abstract Number: 0655 • ACR Convergence 2020
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
Kristian Zobbe¹, Robin Christensen², Sabrina Mai Nielsen³, Lisa Stamp⁴, Marius Henriksen⁵, Anders Føhrby Overgaard⁶, Lene Dreyer⁷, Filip Krag Knop⁸, Jasvinder Singh⁹, Michael Doherty¹⁰, Pascal Richette¹¹, Arne Astrup¹², Karen Ellegaard¹, Else Marie Bartels¹³, Mikael Boesen¹⁴, Henrik Rindel Gudbergsen¹⁵, Henning Bliddal¹⁵ and Lars Erik Kristensen¹⁶, ¹The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, Denmark, ²Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark, ³The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Frederiksberg, Denmark, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, ⁶The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Sorø, ⁷Department of Rheumatology, Aalborg UnIversity Hospital, Aalborg, Denmark, ⁸Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, Copenhagen, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham UK, Nottingham, United Kingdom, ¹¹Department of Rheumatology, Lariboisière Hospital, Paris, France, ¹²Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark, ¹³Department of Neurology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Frederiksberg, Denmark, Copenhagen, Denmark, ¹⁴Department of Radiology Copenhagen University hospital Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark, ¹⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Frederiksberg, Denmark, ¹⁶The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Despite scarce evidence regarding the effects of weight loss in gout1, international guidelines recommend dietary advice and weight loss as a core management strategy…
Abstract Number: 1628 • ACR Convergence 2020
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Simon Helfgott³, Alexander Hu⁴, Kent Kwas Huston⁵, Jordan Leonard⁶, Kelsey Milligan⁷, Scott Milligan⁷, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³BWH- HMS, Boston, MA, ⁴Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁵Kansas City Physician Partners, Kansas City, MO, ⁶Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁷Trio Health, Louisville, CO, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Pegloticase is approved for severe gout in patients that are intolerant to, or whose disease is ineffectively controlled by, other uric acid lowering therapies…
Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Blanka Stiburkova¹, Yu Toyoda², Katerina Pavelcova¹, Jana Bohata¹, Pavel Ješina³, Yu Kubota², Tappei Takada² and Hiroshi Suzuki², ¹Institute of Rheumatology, Prague, Czech Republic, ²Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
Abstract Number: 1629 • ACR Convergence 2020
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Kimmi Cox³, Simon Helfgott⁴, Alexander Hu⁵, Kent Kwas Huston⁶, Jordan Leonard⁷, Scott Milligan³, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³Trio Health, Louisville, CO, ⁴BWH- HMS, Boston, MA, ⁵Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁶Kansas City Physician Partners, Kansas City, MO, ⁷Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Infusion reactions and other adverse events associated with pegloticase may lead to discontinuation of treatment in patient populations that have already failed or are…
Abstract Number: 0659 • ACR Convergence 2020
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
Megan Leask¹, Nicola Dalbeth², Lisa Stamp³, Tony Merriman⁴, Amanda Phipps-Green⁴, Ruth Topless⁴, James Boocock⁵, Hyon Choi⁶, Keresoma Leaupepe¹ and Eli Stahl⁷, ¹University of Otago, Dunedin, Otago, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago Christchurch, Christchurch, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁷Mt Sinai School of Medicine, New York, NY
Background/Purpose: Polynesian (NZ Māori and Pacific) populations have increased prevalence of gout. Hyperuricaemia is contributed to by increased urate production in the liver via the…
Abstract Number: 0661 • ACR Convergence 2020
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Nick Sumpter¹, Alexa Lupi², Megan Leask³, Tony Merriman⁴, Ana Vazquez² and Richard Reynolds¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Michigan State University, East Lansing, MI, ³University of Otago, Dunedin, Otago, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Gout and hyperuricemia (HU), serum urate (SU) > 6.8 mg/dL, often present in the context of chronic kidney disease. It has long been known…
Abstract Number: 0664 • ACR Convergence 2020
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Ana B. Arevalo¹, Alba Munoz², Faris Haddadin², Karan Sud², Gustavo Contreras², Shane Murray², Yousaf Ali² and Edgar Argulian², ¹Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York, NY, ²Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York
Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…
Abstract Number: 0666 • ACR Convergence 2020
Identification of Intracellular Vacuoles in Synovial Fluid with Calcium Pyrophosphate and Monosodium Urate Crystals
Maria Luisa Peral¹, Irene Calabuig¹, Ana Martín-Carratalá², Mariano Andrés¹ and Eliseo Pascual¹, ¹Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain, ²Universidad Miguel Hernández de Elche, Alicante
Background/Purpose: Synovial fluid analysis using polarized microscopy is the gold standard for the diagnosis of crystal-related arthritis. In our experience, we have noted that, when…
Abstract Number: 0674 • ACR Convergence 2020
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Ruriko Koto¹, Akihiro Nakajima¹, Hideki Horiuchi¹ and Hisashi Yamanaka², ¹Teijin Pharma Limited, Tokyo, Japan, ²Sanno Medical Center, Tokyo, Japan
Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…
Abstract Number: 0675 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers
Zancong Shen¹, Elizabeth Polvent², Vijay Hingorani², Andrea Clouser-Roche², Chris Mikelatis², Rongzi Yan², Shunqi Yan² and Li-Tain Yeh², ¹Arthrosi therapeutics, Laguna Hills, CA, ²Arthrosi Therapeutics Inc, Laguna Hills, CA
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…
Abstract Number: 0677 • ACR Convergence 2020
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
John Botson¹, Paul Peloso², Katie Obermeyer³, Brian LaMoreaux³, Lin Zhao³, Michael Weinblatt⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics plc, Gurnee, IL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Western Washington Medical Group Arthritis Clinic, Bothell, WA
Background/Purpose: Consistent, though limited, published data suggests that methotrexate (MTX) improves treatment response in patients treated with pegloticase for uncontrolled (refractory) gout. Recent case series1-3…
Abstract Number: 0680 • ACR Convergence 2020
Sustained Treat to Target Uric Acid Lowering Therapy Markedly Lowers Fatty Acids Levels in Gout Patients
Monica Guma¹, Roxana Coras², Ru Liu-Bryan³ and Robert Terkeltaub⁴, ¹Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³Department of Medicine, VAMC/University of California San Diego, San Diego, ⁴VA Medical Center/UC San Diego, San Diego, CA
Background/Purpose: Though hyperuricemia is implicated in cardiovascular disease, the metabolic syndrome, and type 2 diabetes in both gout and in asymptomatic patients, the core metabolism…
Abstract Number: 0685 • ACR Convergence 2020
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
Herbert S. Baraf¹, Hope Rainey², Peter Lipsky² and Peter Lipsky³, ¹The Ctr for Rheumatology and Bone Research, Wheaton, MD, ²AMPEL BioSolutions LLC., Charlottesville, VA, ³RILITE Foundation, Charlottesville, VA
Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…
Abstract Number: 0110 • ACR Convergence 2020
Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation
Nicola Dalbeth¹, Anne Horne², Borislav Mihov¹, Tony Merriman³, Gregory Gamble¹, Lisa Stamp⁴ and Ian Reid¹, ¹University of Auckland, Auckland, New Zealand, ²The University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand
Background/Purpose: Observational studies have reported that serum urate positively correlates with bone mineral density (BMD) and that hyperuricaemia is protective for the development of osteoporosis…
Abstract Number: 0690 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate in Patients with Gout in a Phase 2a Study
Li-Tain Yeh¹, Elizabeth Polvent¹, Zancong Shen², Vijay Hingorani¹, Andrea Clouser-Roche¹, Chris Mikelatis¹, Shunqi Yan¹ and Rongzi Yan¹, ¹Arthrosi Therapeutics Inc, Laguna Hills, CA, ²Arthrosi therapeutics, Laguna Hills, CA
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. Phase 1 single…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].